China’s Zhifei Biological Products (SHE: 300122), a developer of vaccines and biological products, plans to acquire Chenan Biopharmaceutical.
Zhifei will enter the metabolic diseases field by acquiring Chenan, which currently has six drug candidates that have entered clinical studies.
These candidates include the GLP-1 derivative liraglutide and the insulin degludec, which have completed Phase III studies, while the firm is in late-stage testing of the injectable recombinant semaglutide, the active ingredient in Novo Nordisk's (NOVN: VX) diabetes drug Ozempic and its big-selling obesity treatment Wegovy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze